{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:12Z","timestamp":1792705032211,"version":"4.5.0"},"reference-count":97,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Breast cancer accounts for about 30% of all new female cancers each year, and its incidence is increasing 0.6% per year. An enhanced understanding of the molecular mechanisms of carcinogenesis has led to the development of constantly evolving strategies for local and systemic therapies. Perioperative chemotherapy, immunotherapy, and endocrine therapy play pivotal roles in the overall treatment plan. Guidelines on the appropriate use of these drugs in patients undergoing extirpative breast surgery and\/or breast reconstruction are lacking. Clear indications for the management of systemic therapies relative to the timing of surgery is crucial to ensure consistent treatment outcomes and to minimize complications. Our purpose is to propose evidence-based recommendations to optimize the perioperative management of systemic therapies in patients undergoing breast cancer surgery and breast reconstructive surgery. In this review, we outline the basic tenets of breast cancer therapies, provide an overview on wound-healing principles, delineate relevant pharmacodynamic concepts, summarize literature and pharmacologic data from various preclinical studies and clinical trials, and propose treatment recommendations. Synopsis: This review proposes evidence-based recommendations regarding systemic therapies management for outcome optimization in the perioperative period in breast cancer patients.<\/jats:p>","DOI":"10.3390\/curroncol32030154","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:46:52Z","timestamp":1741585612000},"page":"154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations"],"prefix":"10.3390","volume":"32","author":[{"given":"Mariem","family":"Galuia","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, AdventHealth Hospital, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Fedorova","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"McHayleh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AdventHealth Hospital, Altamonte Springs, FL 32701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mamounas","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, AdventHealth Hospital, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-0409","authenticated-orcid":false,"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8812-7548","authenticated-orcid":false,"given":"Sabrina","family":"Pavri","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, Department of Surgery, AdventHealth Hospital, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2024, December 30). Key Statistics for Breast Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006","volume":"18","author":"Kaufmann","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_3","unstructured":"NCCN Guidelines (2024, December 30). Breast Cancer, Version 2. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0748-7983(97)80135-7","article-title":"Surgical complications related to peri-operative adjuvant chemotherapy in breast cancer. Results of a prospective, controlled, randomized clinical trial","volume":"23","author":"Canavese","year":"1997","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_5","first-page":"9","article-title":"Preoperative or postoperative doxorubicin hydrochloride (adriamycin): Which is better for wound healing?","volume":"100","author":"Lawrence","year":"1986","journal-title":"Surgery"},{"key":"ref_6","first-page":"119","article-title":"Doxorubicin-induced impairment of wound healing in rats","volume":"76","author":"Lawrence","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00000658-199102000-00006","article-title":"Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity","volume":"213","author":"Broadwater","year":"1991","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archsurg.2010.163","article-title":"Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction","volume":"145","author":"Itakura","year":"2010","journal-title":"Arch. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PRS.0b013e3181da8699","article-title":"Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction","volume":"126","author":"Azzawi","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00000637-199903000-00002","article-title":"Immediate breast reconstruction with the TRAM flap after neoadjuvant therapy","volume":"42","author":"Deutsch","year":"1999","journal-title":"Ann. Plast. Surg."},{"key":"ref_11","unstructured":"(2024, December 30). StatPearls Publishing, Available online: https:\/\/www.ncbi.nlm.nih.govbooksNBK554498#:~:text=Even%20further%2C%2094%20to%2097,thus%20will%20be%20considered%20eliminated."},{"key":"ref_12","unstructured":"Bedford Laboratories (2012). Doxorubicin (Adriamycin): Package Insert, Bedford Laboratories."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/1097-0142(19800601)45:11<2811::AID-CNCR2820451116>3.0.CO;2-7","article-title":"A study of adriamycin-reduced wound breaking strength in rats: An evaluation by light and electron microscopy, induction of collagen maturation, and hydroxyproline content","volume":"45","author":"Devereux","year":"1980","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0022-4804(90)90190-D","article-title":"The effect of interleukin-2 administration on wound healing in adriamycin-treated rats","volume":"49","author":"DeCunzo","year":"1990","journal-title":"J. Surg. Res."},{"key":"ref_15","unstructured":"Awosika, A.O., Farrar, M.C., and Jacobs, T.F. (2024). Paclitaxel, StatPearls Publishing."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.jddst.2020.101959","article-title":"Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer","volume":"60","author":"Imran","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_17","unstructured":"Bristol-Myers Squibb (2010). Paraplatin (Carboplatin) Injection, Bristol-Myers Squibb Company. Prescribing Information."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/gyno.1993.1274","article-title":"The effect of immediate intraperitoneal carboplatinum on wound healing","volume":"51","author":"Hopkins","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"ref_19","first-page":"3","article-title":"Gemcitabine: Metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol."},{"key":"ref_20","unstructured":"Lilly (2024, December 30). Gemzar (Gemcitabine) for Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020509s082lbl.pdf."},{"key":"ref_21","first-page":"1213","article-title":"Histological evaluation of colonic anastomotic healing during perioperative Capecitabine administration. Experimental study in rats","volume":"22","author":"Konstantinidis","year":"2007","journal-title":"Histol. Histopathol."},{"key":"ref_22","first-page":"1","article-title":"Capecitabine provides low toxicity antitumor chemotherapy during perioperative period of colectomy: Experimental study in rats","volume":"4","author":"Konstantinidis","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1610722","DOI":"10.3389\/pore.2022.1610722","article-title":"Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer","volume":"28","author":"Paszt","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_24","unstructured":"Rosemont Pharmaceuticals (2024, December 30). Soltamox (Tamoxifen Citrate) Oral Solution, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021807s005lbl.Pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bjps.2017.05.046","article-title":"Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction","volume":"70","author":"Billon","year":"2017","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_26","unstructured":"Astrazeneca (2024, December 30). Faslodex (Fulvestrant) Injection, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2019\/021344orig1s039lbl.Pdf."},{"key":"ref_27","unstructured":"Menarini Group Company (2024, December 30). Orserdu (Elacestrant) Tablets, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2023\/217639s000lbl.Pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Protocol Supplement to: Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized Phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","unstructured":"Novartis (2024, December 30). Femara (Letrozole) Tablets, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2014\/020726s027lbl.Pdf."},{"key":"ref_30","unstructured":"Arimidex (2024, December 30). Arimidex (Anastrozole) Tablet, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2011\/020541s026lbl.Pdf."},{"key":"ref_31","unstructured":"Pfizer (2024, December 30). Aromasin (Exemestane) Tablets, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2018\/020753s020lbl.Pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"ref_33","unstructured":"Merck Sharp, and Dohme Corp (2024, December 30). Keytruda (Pembrolizumab) for Injection, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.Pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2019.12.019","article-title":"Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: Prospective assessment of perioperative outcomes from the PURE-01 trial","volume":"77","author":"Briganti","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jtcvs.2021.02.099","article-title":"Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer","volume":"163","author":"Tong","year":"2022","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.21037\/jtd-21-103","article-title":"Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma","volume":"13","author":"Shen","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11912-022-01202-6","article-title":"Cancer immunotherapies: What the perioperative physician needs to know","volume":"24","author":"Ackerman","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_38","first-page":"55","article-title":"Mechanisms contributing to Ado-trastuzumab emtansine-induced toxicities: A gateway to better understanding of ADC-associated toxicities","volume":"4","author":"Endo","year":"2021","journal-title":"Antib. Ther."},{"key":"ref_39","unstructured":"Kadcyla (ado-trastuzumab emtansine) for injection. Prescribing information. Genentech."},{"key":"ref_40","unstructured":"Daiichi Sankyo (2024, December 30). Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) for Injection, Available online: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2022\/761139s021lbl.Pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_45","unstructured":"Gilead (2024, December 30). Trodelvy (Sacituzumab Govitecan-Hziy) for Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomized, open-label, multicenter, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_47","unstructured":"Genetech (2024, December 30). Herceptin (Trastuzumab), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5256lbl.pdf."},{"key":"ref_48","unstructured":"Genetech (2024, December 30). Perjeta (Pertuzumab), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125409lbl.pdf."},{"key":"ref_49","unstructured":"Genetech (2024, December 30). Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761170s000lbl.pdf."},{"key":"ref_50","unstructured":"The ASCO Post (2024, December 30). Relationship Between Targeted HER2 Therapy and Breast Reconstruction. Available online: https:\/\/ascopost.com\/News\/58130#:~:text=Trastuzumab%20(Herceptin)%20therapy%20for%20breast,%20The%20American%20College%20of%20Surgeons."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.amjsurg.2020.06.053","article-title":"Evaluation of breast surgical oncology complications after single agent versus dual agent targeted HER2 therapy and breast reconstruction","volume":"220","author":"Cullom","year":"2020","journal-title":"Am. J. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jamcollsurg.2017.08.023","article-title":"Association between targeted HER-2 therapy and breast reconstruction outcomes: A propensity score-matched analysis","volume":"225","author":"Shammas","year":"2017","journal-title":"J. Am. Coll. Surg."},{"key":"ref_53","unstructured":"GlaxoSmithKline (2024, December 30). Tykerb (Lapatinib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf."},{"key":"ref_54","unstructured":"Seagen (2024, December 30). Tukysa (Tucatinib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213411s000lbl.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1158\/1078-0432.CCR-14-1428","article-title":"Antiproliferative effect of Lapatinib in HER2-positive and HER2-negative\/HER3-high breast cancer: Results of the presurgical randomized MAPLE trial (CRUK E\/06\/039)","volume":"21","author":"Leary","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.2012.44.8027","article-title":"Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006","volume":"31","author":"Rimawi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/wound.2013.0496","article-title":"Anti-angiogenic drugs: Involvement in cutaneous side effects and wound-healing complication","volume":"3","author":"Bodnar","year":"2014","journal-title":"Adv. Wound Care"},{"key":"ref_58","unstructured":"Neratinib (2024, December 30). Data on File: [ExteNET Protocol]. A Randomized, Double-Blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage her-2\/neu Overexpressed\/Amplified Breast Cancer. Available online: https:\/\/www.dana-farber.org\/clinical-trials\/09-279."},{"key":"ref_59","unstructured":"(2024, December 30). A Study of Tucatinib Given Before Surgery to People with HER2-Positive Cancers That Have Spread to the Brain. Available online: https:\/\/www.mskcc.org\/cancer-care\/clinical-trials\/22-168."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40264-014-0139-x","article-title":"Effect of tyrosine kinase inhibitors on wound healing and tissue repair: Implications for surgery in cancer patients","volume":"37","author":"Shah","year":"2014","journal-title":"Drug Saf."},{"key":"ref_62","unstructured":"Pfizer (2024, December 30). Ibrance (Palbociclib) Capsules, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207103s008lbl.pdf."},{"key":"ref_63","unstructured":"Novartis (2024, December 30). Kisqali (Ribociclib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209092s013,209935s021lbl.pdf."},{"key":"ref_64","unstructured":"Lilly (2024, December 30). Verzenio (Abemaciclib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208716s006s007s008lbl.pdf."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Fasching, P., Jerusalem, G., Pivot, X., Martin, M., De Laurentiis, M., Blackwell, K., Esteva, F.J., Paquet-Luzy, T., Tang, Z., and Lorenc, K.R. (2015, January 8\u201311). Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients with HR+, HER2- advanced breast cancer who have received no, or only one line of prior endocrine treatment: MONALEESA-3. Proceedings of the San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, USA. Poster OT2-01-02.","DOI":"10.1158\/1538-7445.SABCS15-OT2-01-02"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor positive, advanced breast cancer (MONALEESA-7): A randomized phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential 7 toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: Practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_72","unstructured":"Novartis (2023, December 30). Afinitor (Everolimus) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022334s6lbl.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2011-0078","article-title":"A phase II trial of bevacizumab plus everolimus for 80 patients with refractory metastatic colorectal cancer","volume":"16","author":"Altomare","year":"2011","journal-title":"Oncologist"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-14-1998","article-title":"A translational, pharmacodynamic and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer","volume":"21","author":"Owonikoko","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_76","unstructured":"Novartis (2024, December 30). Piqray (alpelisib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212526s000lbl.pdf."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.breast.2021.12.016","article-title":"A multidisciplinary approach to optimizing care of patients treated with alpelisib","volume":"61","author":"Rugo","year":"2022","journal-title":"Breast"},{"key":"ref_80","unstructured":"AstraZeneca (2024, December 30). Lynparza (Olaparib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s025lbl.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.drudis.2020.04.019","article-title":"\u2019PARP\u2019ing fibrosis: Repurposing poly (ADP ribose) polymerase (PARP) inhibitors","volume":"25","author":"Rao","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [supplementary appendix]","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bph.13735","article-title":"The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury","volume":"175","author":"Ahmad","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_88","unstructured":"(2024, December 30). Olaparib in Treating Patients with Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03943173?tab=results."},{"key":"ref_89","unstructured":"AstraZeneca (2024, December 30). Truqap (Capivasertib) Tablets, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/218197s000lbl.pdf."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000454919","article-title":"Skin wound healing: An update on the current 100 knowledge and concepts","volume":"58","author":"Sorg","year":"2017","journal-title":"Eur. Surg. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12s","DOI":"10.1097\/01.prs.0000225430.42531.c2","article-title":"The basic science of wound healing","volume":"117","author":"Broughton","year":"2006","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature07039","article-title":"Wound repair and regeneration","volume":"453","author":"Gurtner","year":"2008","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.276.5309.75","article-title":"Wound healing: Aiming for perfect skin regeneration","volume":"276","author":"Martin","year":"1997","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cps.2012.04.003","article-title":"Harnessing growth factors to influence wound healing","volume":"39","author":"Kiwanuka","year":"2012","journal-title":"Clin. Plast. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199909023411006","article-title":"Cutaneous wound healing","volume":"341","author":"Singer","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/GOX.0b013e31828ff9f4","article-title":"The role of wound healing and its everyday application in plastic surgery: A practical perspective and systematic review","volume":"1","author":"Ireton","year":"2013","journal-title":"Plast. Reconstr. Surg. Glob. Open"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:36Z","timestamp":1760028576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":97,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030154"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030154","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]}}}